Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy

Conclusion: 177Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal associated toxicity seen in both our T-naïve and heavily pretreated patient cohorts.

Source: Journal of Nuclear Medicine - June 30, 2019 Category: Nuclear Medicine Authors: Barber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., Baum, R. P. Tags: Clinical Source Type: research